Evotec unveiled a multi-year restructuring named 'Horizons' that will eliminate up to 800 positions—about one-sixth of its workforce—and close four facilities across Europe and the U.S. The company said the changes will concentrate scientific expertise into new 'Centers of Excellence' and reduce costs between 2026 and 2030 to accelerate growth and customer responsiveness. Sites slated for shutdown include Abingdon (UK), Framingham (MA), Lyon (France) and Munich (Germany). Evotec emphasized that core hubs—such as biologics sites in Seattle and Redmond, and discovery hubs in Princeton—will remain operational. Management framed the cuts as a strategic refocus toward higher-value discovery and preclinical segments while preserving key client-facing capabilities. The restructuring signals continued consolidation pressure on integrated drug-discovery service providers as biopharma rebalances outsourced workflows and as CDMOs and CROs optimize footprints for biologics and advanced modalities.